FDA Grants AP Status for Valproic Acid ANDA073229 by Catalent
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Valproic Acid submitted by Catalent.
Asset / Drug
Drug and asset intelligence for Catalent with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.